Johnson & Johnson Q1 Sales Expected Up, Profit Down Ahead of Earnings Report
JNJ sits 62% above its 52-week low of $145.13 on light trading volume (0.3× avg).
Summary
Johnson & Johnson is expected to report higher first-quarter sales of $23.61 billion, driven by growth in its pharmaceutical and medical device segments. However, net income is forecast to decline significantly to $6.11 billion, with adjusted earnings per share also expected to be lower year-over-year. This earnings preview provides key analyst expectations for the upcoming report, highlighting the mixed outlook of revenue growth against profit contraction. Traders will be watching the actual results closely, particularly the impact of declining Stelara sales due to patent expiry, which is expected to moderate after a sharp drop in the prior quarter.
At the time of this announcement, JNJ was trading at $235.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $567.3B. The 52-week trading range was $145.13 to $251.71. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.